We have previously demonstratedthe benefits to utilizing the LPA–LPAR1axis for targeting MBC in an animal tumor model.42,43 Given the structure of the binding site of LPAR1,38,39 selective LPAR1 antagonists are mostly water-insoluble; therefore,lipid nanoparticles (e.g., liposomes) are an ideal platform for deliverysince these drugs can be embedded into the lipid bilayer. Here, LPAR1 is linked to neoplasm.